Navigation Links
Genaera Corporation to Present at BIO Business Forum
Date:6/12/2008

ning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding the preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborator, in connection with the development and commercialization of Genaera's IL-9 antibody program; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and
'/>"/>
SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genaera Corporation Announces First Quarter Financial Results
2. Genaera Corporation Announces 2007 Financial Results
3. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
4. Genaera Corporation Announces Third Quarter Financial Results
5. Genaera to Present at Biotech 2007 and BIO InvestorForum
6. Genaera Elects New Board Member and Announces Executive Appointments
7. Met-Pro Corporations Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000
8. Veridex Announces Agreement to Acquire the Assets of Immunicon Corporation
9. Environmental Tectonics Corporations BioMedical Systems Division Awarded Contract for Multiple Monoplace Chambers
10. BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer
11. DURECT Corporation to Participate in Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... An increase of awareness related to benefits ... food nutrients, regulatory changes and concerns related to consumer ... for natural astaxanthin over the past few years. Producers ... capacities to satisfy the rising demand. , The ... (used in nutraceuticals, aqua feed, food and beverages and ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 Researchers ... in nanoparticle technology that will enable broader and ... other diseases with a simple breath screen. The ... the U.S. Food and Drug Administration (FDA) approval ... of the innovative Nanoparticle Biomarker Tagging device. , ...
(Date:3/25/2015)... , March 25, 2015  18 piglets ... of intense research by scientists in the College of ... and represent a breakthrough in the field of ... in the Department of Animal & Avian Sciences (ANSC) ... in ANSC, successfully produced genome-edited pigs using a ...
(Date:3/25/2015)... , March 25, 2015   Demy-Colton Life ... targeted investor and business development conferences exclusively for the ... is launching the Biotech CEO Summit. ... meeting that brings together biotech industry leaders who are ... and innovation while reaping the rewards of biotech,s new ...
Breaking Biology Technology:Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3University of Maryland Researchers Successfully Produce Genome-edited Pigs Using Revolutionary Technology 2Biotech CEO Summit to Bring Key Biotech Leaders Together in Industry Brain Trust 2
... SAN DIEGO, Nov. 8, 2010 Vet-Stem, Inc. announced ... LTD (AVSC) has been completed which secures Vet-Stem,s third ... veterinarians for treating horses, dog and cats.  AVSC is ... services in Australia, New Zealand and Singapore.   ...
... Savara Inc., an inhalation product development company, today ... Board of Directors. In 1983 Mr. Hawkins ... guided the growth of that organization to over 700 ... largest clinical contract research organizations in the world. Since ...
... ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
Cached Biology Technology:Vet-Stem Signs License Agreement With Affiliate in Australia for Veterinary Stem Cells 2Savara Announces Appointment of Pharmaceutical Veteran to Board of Directors 2OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 2OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 3OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 4OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 5OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 6OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 7OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 8OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 9
(Date:3/23/2015)...   HOYOS Labs , a leading global authentication ... the Company will demonstrate multiple biometrics-based technologies under its ... Connect:ID on March 23 through 25, 2015, in ... the IEEE Biometric Open Protocol Standard; free biometrics-based consumer ... control system. BOPS was invented by HOYOS Labs and ...
(Date:3/20/2015)... Mar. 20, 2015 Research and Markets ... of the "India Sensors Market Forecast and ... The sensor market is projected to grow ... Consumer electronics, automotive, industrial and healthcare sectors ... the country. In addition, adoption of MEMS technology ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report to ... for Iris Biometrics in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Latin America . ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... with environmental threats like bad weather, predators or oil ... researchers have analyzed blood samples to detect corticosterone levels ... have shown that corticosterone spikes can also be detected ... in the May 11 online edition of " Journal ...
... From hot pink to traditional French and Lady Gaga,s sophisticated ... But they are not just pretty when nails appeared ... million years ago, they led to the development of critical ... the ability to grasp, whether it,s a nail polish brush ...
... has seeded the Salk Institute as the number one research ... plant biologists, Joe Ecker, Ph.D., Joanne Chory, Ph.D. Jeff Long, ... the number of highly cited papers with the most impact, ... world with the greatest number of highly cited papers (top ...
Cached Biology News:A tool to measure stress hormone in birds -- feathers 2Researchers discover oldest evidence of nails in modern primates 2Researchers discover oldest evidence of nails in modern primates 3Salk Institute named global leader in plant biology research 2
... form of cell suicide, which follows a ... of this process is a cascade of ... participate in a series of reactions that ... and result in the cleavage of protein ...
...
...
Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
Biology Products: